drugset / Trial / NCT04093466
A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors
Phase 1
Recruiting
126 enrolled
Beijing Konruns Pharmaceutical Co., Ltd.
Beijing Tongren Hospital · collabChinese Academy of Medical Sciences · collabWest China Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of CX1003 in patients with refractory advanced or metastatic solid tumors.
Timeline
- Start
- 2020-04-27
- Primary completion
- 2025-10
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CX1003 | Small molecule | 25 mg | Oral |
| Subject | CX1003 | Small molecule | 50 mg | Oral |
| Subject | CX1003 | Small molecule | 75 mg | Oral |
| Subject | CX1003 | Small molecule | 100 mg | Oral |
| Subject | CX1003 | Small molecule | 125 mg | Oral |
| Subject | CX1003 | Small molecule | 150 mg | Oral |
| Subject | CX1003 | Small molecule | 175 mg | Oral |